社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Rocket Pharmaceuticals, Inc.(RCKT)
盘前
4.92
0.00
0.00%
04:14 EDT
4.92
-0.04
-0.81%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
科迪勒拉
·
02-18
SGMO : 盗骊追风---马年冲刺与估值变数
谁热爱光明，光明就热爱谁。——纪伯伦 在我的新年16黑马组合中，最受虎友关注的是Sangamo,部分原因可能是股价更便宜，更有想象空间吧？事实上，单价高的长得更快，大家去看看
$Praxis Precision Medicines, Inc.(PRAX)$
经历2500万美元增发带来的股价颠簸后，它最近有走稳趋向。估计持仓虎友仍不太放心，因它仍面临4月27日前的一个合股可能。为此，我今天拚凑一篇小文讲下它的基本面进展，及未来前景。内容基于我的最新调研，仅供虎友们参考： 一 公司当前在做什么 管理层近日与杰富瑞交流中表示： BLA提交：法布里基因疗法滚动提交已启动。4个模块中的3个（含临床数据）本月交完。正在等待CMC稳定性数据，预计2026年二季度全部完成。 合作洽谈：一直在继续Fabry商业化合作讨论，随着资产在监管进程中推进（BLA受理到审评），法布里项目的价值会越来越高，这会给合作伙伴谈判施加额外压力。 ST-503：AAV载体锌指抑制基因疗法，沉默SCN9A/Nav1.7 在顽固性小纤维神经疼痛中的作用，1/2期试验启动，4个招募点。 ST-506: 首个使用STAC-BBB载体的临床项目，治疗发病几个月内死亡率100%的朊病毒感染，正在准备向英国提交的新药申请。 二 法布里项目的疗效 前几天在世界大会上公布的详细数据显示： 心脏功能： 31/32名患者NT-proBNP和肌钙蛋白T稳定。这意味着没有心衰压力，没有心肌损伤。LVMI和QTc也稳定，没有心律失常的危险 肾脏： eGFR斜率逆转。第16周时还在下降（-3.6 mL/min/年）。第52周：+1.96。第104周：+1.74持续。FDA同意公司的计算方法。 机制： 清除足细胞中的lyso-GB3 → 炎症消退 → 亚功能肾单位
SGMO : 盗骊追风---马年冲刺与估值变数
精彩
乔木何许:
科兄，老虎证券新用户无法下载app，换了一台新手机，然后就无法下载了！您还用什么app看美股吗？
回复
12
点赞
23
编组 21备份 2
分享
举报
科迪勒拉
·
01-08
围猎指南---如何找出“有望大放异彩”的创新药股票？
“你们工作，学习，因而能跟上大地的步伐，领会大地的精神” ——纪伯伦 在公布我的“2026年10大美股“之前，本老哥先把收藏许久的创新药股票“围猎指南”，分享给追求卓越的诸位虎友，为的是互相学习，共同进步。说明如下： 一、本指南的底层逻辑在科技投资领域具有普世性，其核心宗旨： 价值理念，科学评估 ，理性介入， 二、今后，投资理念、方法论等内容将不再被专题阐述，因我已言无不尽，多说皆为重复。若有虎友想深入学习，可翻阅以前的小文： （1）蒙蒂尔十大投资信条解读系列； （2）论投资“确定性”及相关策略； （3） 策略正确，胜率才有意义； （4）屡败屡战！四大亏钱法则，你中了几个？ （5） 散户及新手最容易跳进的三大陷阱； （6） 如何在美股市场进行风险投资？ （7）十个迹象表明你的公司即将被收购； （8） 投资很简单，前提是你要保持简单； （9） 如何区分估值过高与股票泡沫？ （10） 如何解读长期主义？ （11） 世界由二八法则支配； （12） 最宝贵的优胜股源泉； 正文如下： 一 筛选投资者持怀疑情绪的目标（良好的风险/回报比）： （1）在关键催化剂前，投资人预期较低 （2）先前数据明确、疗法模式疲劳、或对靶点/适应症持怀疑情绪 二 识别能推动进展的数据催化剂 （1）核心问题：这将对获批概率产生多大影响？ （2）重点关注注册性研究和II期后期临床试验 （3）巨大的峰值销售额往往有助于并购溢价，可能带来持续的股价上涨 三 聚焦清晰的发展路径 （1）小分子及其他成熟疗法模式 （2）明确的监管临床终点 （3）清晰的下一步（新药申请/NDA/生物制品许可申请/BLA） 四 生物学复杂且难以预测 （1）并非所有符合这些标准的情况都能成功 （2）尽管分析全面且数据充分，仍无法在许多情况下建立高度信心。 （3）优势来自于市场所忽视的、有依据且差异化的投资逻辑
围猎指南---如何找出“有望大放异彩”的创新药股票？
精彩
huuou:
指南太牛了，生物科技股有戏！
回复
2
点赞
10
编组 21备份 2
分享
举报
科迪勒拉
·
01-04
火箭制药（RCKT) : 发射倒计时，双引擎基因疗法将迎来关键一跃
除了通过黑夜的道路，人们不能到达黎明。——纪伯伦 这是本老哥新年第一股深度分析，欢迎读者们进来交流讨论。 一 公司简介 火箭制药是一家专注于开发罕见病基因疗法的临床阶段生物技术公司。公司建立了双重的技术平台：一是基于慢病毒的体外基因疗法平台，主要用于治疗血液系统罕见病；二是基于腺相关病毒的体内基因疗法平台，主要用于治疗心脏及神经肌肉疾病。 二 核心管线进展 1. 达农病基因疗法 (RP-A501) 达农病是一种由 LAMP2基因突变引起的X连锁显性遗传病。该突变导致细胞自噬过程受损，糖原和自噬体在心脏、肌肉等组织中异常堆积，从而引发严重且进展迅速的心肌病、骨骼肌无力及智力障碍。男性患者病情尤为凶险，常于青春期或成年早期因心力衰竭死亡，目前除心脏移植外无有效疗法。据公司估计，欧美市场的患者规模约为 15000至30000人。 该管线的关键进展在于其AAV9载体基因疗法RP-A501。该疗法在2025年经历了一次临床暂停挫折，因一位受试者患毛细血管渗漏综合征死亡，但不到3个月之内，公司与FDA达成一致，临床搁置被解除。 公司以调整后的方案（采用3.8 × 10¹³ GC/kg的剂量）重新开始患者给药。此前，基于积极的I期临床数据，该疗法已获得FDA授予的再生医学先进疗法资格，数据显示其能有效修复LAMP2蛋白表达，并在心脏结构和功能等多个终点上表现出持久的改善或稳定。FDA也已认可其采用自然史对照的单臂II期关键试验设计，为其潜在的加速批准路径奠定了基础。 2. 白细胞粘附缺陷症I型基因疗法 (KRESLADI) 白细胞粘附缺陷症I型是一种由 ITGB2基因突变 导致CD18整合素缺陷的罕见常染色体隐性遗传病。该缺陷使得患者白细胞无法迁移至感染部位，导致出生后即出现危及生命的反复严重感染、伤口难以愈合及脐带脱落延迟。重度患者若不接受成功的造血干细胞移植，死亡率极高。该疾病极为罕
火箭制药（RCKT) : 发射倒计时，双引擎基因疗法将迎来关键一跃
精彩
一雨成烟:
老哥我全仓all in。还是拿20%买
回复
6
点赞
8
编组 21备份 2
分享
举报
中文投资网
·
2025-05-27
【盘前必读】特朗普推迟对欧关税美股期指全面走高，新药试验患者突发去世RCKT重挫六成
本交易日盘前，美股股指期货全面走高，道指涨逾500点，纳斯达克期指涨逾300点，特朗普宣布推迟对欧关税的消息提振了市场，盘前欧洲主要股市也纷纷走高。美国总统唐纳德·特朗普与欧盟委员会主席乌尔苏拉·冯德莱恩通话后，同意将原定于6月1日对欧盟进口商品征收50%关税的计划推迟至7月9日，以便为贸易谈判争取更多时间。个股方面，Rocket Pharmaceuticals宣布，FDA在一名因使用该药物而出现并发症的患者去世后停止了其对Danon病的研究性疗法的试验，盘前股价暴跌六成。中国电商巨头拼多多每股收益和营业收入均大幅不及市场预期，盘前大幅下跌。Skyline Champion每股收益和营业收入均不及市场预期，盘前股价大幅下跌。投资者关注日内经济数据和公司财报。欧洲方面，特朗普推迟关税期限提振投资者情绪，欧洲主要股市小幅走高。石油小幅下跌，黄金大幅走低。美股期指：道琼斯工业股票平均价格指数期货+571.93点，报42239点；纳斯达克100指数期货+327.84点，报21296.5点，标准普尔500股指期货+84.68点，报5900.5点。海外市场：英国富时100指数+0.76%，德国DAX 30指数+0.72%，法国CAC 40指数+0.16%，中国上证指数-0.18%，香港恒生指数+0.43%，日经225指数+0.51%。数据方面投资者可以关注：8:30 4月耐用品订单月率9:00 3月FHFA房价指数月率9:00 3月S&P/CS20座大城市未季调房价指数年率10:00 5月咨商会消费者信心指数10:30 5月达拉斯联储商业活动指数AutoZone(AZO)第三季度每股收益为35.36美元，比市场预期值37.11美元低1.75美元；营收同比增长5.4至44.6亿美元，市场预期值44.2亿美元。Skyline Champion (SKY)第四季度每股收益为0.65美
【盘前必读】特朗普推迟对欧关税美股期指全面走高，新药试验患者突发去世RCKT重挫六成
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
Rocket Pharmaceuticals, Inc.
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.rocketpharma.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Rocket Pharmaceuticals, Inc.于1999年7月7日根据特拉华州法律注册成立。该公司是一家完全整合的、处于后期阶段的生物技术公司，专注于开发首创、唯一和同类最佳的基因疗法，具有直接的靶向作用机制和明确的临床终点，用于罕见和破坏性疾病。
03-11 05:24
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
02-26
年度报告
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
02-26
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
02-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-13
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-13
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-13
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-13
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-18
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
2025-11-06
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
分时
5日
日
周
月
数据加载中...
最高
5.07
今开
4.90
量比
0.44
最低
4.80
昨收
4.96
换手率
2.20%
热议股票
{"pagemeta":{"title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rocket Pharmaceuticals, Inc.,RCKT,Rocket Pharmaceuticals, Inc.股票,Rocket Pharmaceuticals, Inc.股票老虎,Rocket Pharmaceuticals, Inc.股票老虎国际,Rocket Pharmaceuticals, Inc.行情,Rocket Pharmaceuticals, Inc.股票行情,Rocket Pharmaceuticals, Inc.股价,Rocket Pharmaceuticals, Inc.股市,Rocket Pharmaceuticals, Inc.股票价格,Rocket Pharmaceuticals, Inc.股票交易,Rocket Pharmaceuticals, Inc.股票购买,Rocket Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rocket Pharmaceuticals, Inc.(RCKT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rocket Pharmaceuticals, Inc.(RCKT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"RCKT","data":{"stockData":{"symbol":"RCKT","market":"US","secType":"STK","nameCN":"Rocket Pharmaceuticals, Inc.","latestPrice":4.92,"timestamp":1773345600000,"preClose":4.96,"halted":0,"volume":1730509,"hourTrading":{"tag":"盘前","latestPrice":4.92,"preClose":4.92,"latestTime":"04:14 EDT","volume":1,"amount":4.92,"timestamp":1773389662058,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.008064516129032265,"floatShares":78786291,"shares":108222228,"eps":-2.01,"marketStatus":"盘前交易","change":-0.04,"latestTime":"03-13 05:45:58 EDT","open":4.9,"high":5.07,"low":4.8,"amount":8494673.2596935,"amplitude":0.054435,"askPrice":5.29,"askSize":117,"bidPrice":4.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.01,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773408600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1424235600000,"exchange":"NASDAQ","adjPreClose":4.92,"preHourTrading":{"tag":"盘前","latestPrice":4.92,"preClose":4.92,"latestTime":"04:14 EDT","volume":1,"amount":4.92,"timestamp":1773389662058,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.97,"preClose":4.92,"latestTime":"19:20 EDT","volume":15082,"amount":74611.1909,"timestamp":1773357643885,"change":0.05,"changeRate":0.010163,"amplitude":0.014228},"volumeRatio":0.4365147291236865,"impliedVol":1.943,"impliedVolPercentile":0.828},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.534094573659848","cardData":[{"tweetId":"534094573659848","author":{"authorId":"3484536045691836","idStr":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/3f226f5fd9da51c5782d3e591f0bfe54","userType":2,"introduction":"倾向于进入好的业务，并安静地留在那里。","crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"fanSize":4147,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"SGMO : 盗骊追风---马年冲刺与估值变数","digest":"谁热爱光明，光明就热爱谁。——纪伯伦 在我的新年16黑马组合中，最受虎友关注的是Sangamo,部分原因可能是股价更便宜，更有想象空间吧？事实上，单价高的长得更快，大家去看看 <a href=\"https://laohu8.com/S/PRAX\">$Praxis Precision Medicines, Inc.(PRAX)$</a> 经历2500万美元增发带来的股价颠簸后，它最近有走稳趋向。估计持仓虎友仍不太放心，因它仍面临4月27日前的一个合股可能。为此，我今天拚凑一篇小文讲下它的基本面进展，及未来前景。内容基于我的最新调研，仅供虎友们参考： 一 公司当前在做什么 管理层近日与杰富瑞交流中表示： BLA提交：法布里基因疗法滚动提交已启动。4个模块中的3个（含临床数据）本月交完。正在等待CMC稳定性数据，预计2026年二季度全部完成。 合作洽谈：一直在继续Fabry商业化合作讨论，随着资产在监管进程中推进（BLA受理到审评），法布里项目的价值会越来越高，这会给合作伙伴谈判施加额外压力。 ST-503：AAV载体锌指抑制基因疗法，沉默SCN9A/Nav1.7 在顽固性小纤维神经疼痛中的作用，1/2期试验启动，4个招募点。 ST-506: 首个使用STAC-BBB载体的临床项目，治疗发病几个月内死亡率100%的朊病毒感染，正在准备向英国提交的新药申请。 二 法布里项目的疗效 前几天在世界大会上公布的详细数据显示： 心脏功能： 31/32名患者NT-proBNP和肌钙蛋白T稳定。这意味着没有心衰压力，没有心肌损伤。LVMI和QTc也稳定，没有心律失常的危险 肾脏： eGFR斜率逆转。第16周时还在下降（-3.6 mL/min/年）。第52周：+1.96。第104周：+1.74持续。FDA同意公司的计算方法。 机制： 清除足细胞中的lyso-GB3 → 炎症消退 → 亚功能肾单位","plainDigest":"谁热爱光明，光明就热爱谁。——纪伯伦 在我的新年16黑马组合中，最受虎友关注的是Sangamo,部分原因可能是股价更便宜，更有想象空间吧？事实上，单价高的长得更快，大家去看看 $Praxis Precision Medicines, Inc.(PRAX)$ 经历2500万美元增发带来的股价颠簸后，它最近有走稳趋向。估计持仓虎友仍不太放心，因它仍面临4月27日前的一个合股可能。为此，我今天拚凑一篇小文讲下它的基本面进展，及未来前景。内容基于我的最新调研，仅供虎友们参考： 一 公司当前在做什么 管理层近日与杰富瑞交流中表示： BLA提交：法布里基因疗法滚动提交已启动。4个模块中的3个（含临床数据）本月交完。正在等待CMC稳定性数据，预计2026年二季度全部完成。 合作洽谈：一直在继续Fabry商业化合作讨论，随着资产在监管进程中推进（BLA受理到审评），法布里项目的价值会越来越高，这会给合作伙伴谈判施加额外压力。 ST-503：AAV载体锌指抑制基因疗法，沉默SCN9A/Nav1.7 在顽固性小纤维神经疼痛中的作用，1/2期试验启动，4个招募点。 ST-506: 首个使用STAC-BBB载体的临床项目，治疗发病几个月内死亡率100%的朊病毒感染，正在准备向英国提交的新药申请。 二 法布里项目的疗效 前几天在世界大会上公布的详细数据显示： 心脏功能： 31/32名患者NT-proBNP和肌钙蛋白T稳定。这意味着没有心衰压力，没有心肌损伤。LVMI和QTc也稳定，没有心律失常的危险 肾脏： eGFR斜率逆转。第16周时还在下降（-3.6 mL/min/年）。第52周：+1.96。第104周：+1.74持续。FDA同意公司的计算方法。 机制： 清除足细胞中的lyso-GB3 → 炎症消退 → 亚功能肾单位","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1771413304539,"gmtModify":1771737600034,"symbols":["SLDB","SGMO","SANA","PGEN","PRAX","NTLA","RCKT"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/c3005cce53cb600b3f0b2059d4f46b13","width":"932","height":"692"}],"repostCount":0,"viewCount":17904,"likeCount":23,"liked":false,"collected":false,"commentCount":12,"hotComments":[{"id":"536905238361528","author":{"authorId":"3517179963233203","idStr":"3517179963233203","name":"乔木何许","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"fanSize":1,"starInvestorFlag":false},"content":"科兄，老虎证券新用户无法下载app，换了一台新手机，然后就无法下载了！您还用什么app看美股吗？","plainContent":"科兄，老虎证券新用户无法下载app，换了一台新手机，然后就无法下载了！您还用什么app看美股吗？","likeCount":0,"commentType":"hot","coins":0},{"id":"534107090851168","author":{"authorId":"3573355904555920","idStr":"3573355904555920","name":"刚哥眼里有光","avatar":"https://static.tigerbbs.com/9a9098b763e98a1cc0d52cd00dbf9a9a","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":1,"fanSize":2,"starInvestorFlag":false},"content":"感谢科老师的分享，我们拭目以待","plainContent":"感谢科老师的分享，我们拭目以待","likeCount":0,"commentType":"hot","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":true,"shareLink":"https://laohu8.com/post/534094573659848","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":2892,"displayRows":4,"foldSize":0,"authorId":"3484536045691836"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.519647362978304","cardData":[{"tweetId":"519647362978304","author":{"authorId":"3484536045691836","idStr":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/3f226f5fd9da51c5782d3e591f0bfe54","userType":2,"introduction":"倾向于进入好的业务，并安静地留在那里。","crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"fanSize":4147,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"围猎指南---如何找出“有望大放异彩”的创新药股票？","digest":"“你们工作，学习，因而能跟上大地的步伐，领会大地的精神” ——纪伯伦 在公布我的“2026年10大美股“之前，本老哥先把收藏许久的创新药股票“围猎指南”，分享给追求卓越的诸位虎友，为的是互相学习，共同进步。说明如下： 一、本指南的底层逻辑在科技投资领域具有普世性，其核心宗旨： 价值理念，科学评估 ，理性介入， 二、今后，投资理念、方法论等内容将不再被专题阐述，因我已言无不尽，多说皆为重复。若有虎友想深入学习，可翻阅以前的小文： （1）蒙蒂尔十大投资信条解读系列； （2）论投资“确定性”及相关策略； （3） 策略正确，胜率才有意义； （4）屡败屡战！四大亏钱法则，你中了几个？ （5） 散户及新手最容易跳进的三大陷阱； （6） 如何在美股市场进行风险投资？ （7）十个迹象表明你的公司即将被收购； （8） 投资很简单，前提是你要保持简单； （9） 如何区分估值过高与股票泡沫？ （10） 如何解读长期主义？ （11） 世界由二八法则支配； （12） 最宝贵的优胜股源泉； 正文如下： 一 筛选投资者持怀疑情绪的目标（良好的风险/回报比）： （1）在关键催化剂前，投资人预期较低 （2）先前数据明确、疗法模式疲劳、或对靶点/适应症持怀疑情绪 二 识别能推动进展的数据催化剂 （1）核心问题：这将对获批概率产生多大影响？ （2）重点关注注册性研究和II期后期临床试验 （3）巨大的峰值销售额往往有助于并购溢价，可能带来持续的股价上涨 三 聚焦清晰的发展路径 （1）小分子及其他成熟疗法模式 （2）明确的监管临床终点 （3）清晰的下一步（新药申请/NDA/生物制品许可申请/BLA） 四 生物学复杂且难以预测 （1）并非所有符合这些标准的情况都能成功 （2）尽管分析全面且数据充分，仍无法在许多情况下建立高度信心。 （3）优势来自于市场所忽视的、有依据且差异化的投资逻辑","plainDigest":"“你们工作，学习，因而能跟上大地的步伐，领会大地的精神” ——纪伯伦 在公布我的“2026年10大美股“之前，本老哥先把收藏许久的创新药股票“围猎指南”，分享给追求卓越的诸位虎友，为的是互相学习，共同进步。说明如下： 一、本指南的底层逻辑在科技投资领域具有普世性，其核心宗旨： 价值理念，科学评估 ，理性介入， 二、今后，投资理念、方法论等内容将不再被专题阐述，因我已言无不尽，多说皆为重复。若有虎友想深入学习，可翻阅以前的小文： （1）蒙蒂尔十大投资信条解读系列； （2）论投资“确定性”及相关策略； （3） 策略正确，胜率才有意义； （4）屡败屡战！四大亏钱法则，你中了几个？ （5） 散户及新手最容易跳进的三大陷阱； （6） 如何在美股市场进行风险投资？ （7）十个迹象表明你的公司即将被收购； （8） 投资很简单，前提是你要保持简单； （9） 如何区分估值过高与股票泡沫？ （10） 如何解读长期主义？ （11） 世界由二八法则支配； （12） 最宝贵的优胜股源泉； 正文如下： 一 筛选投资者持怀疑情绪的目标（良好的风险/回报比）： （1）在关键催化剂前，投资人预期较低 （2）先前数据明确、疗法模式疲劳、或对靶点/适应症持怀疑情绪 二 识别能推动进展的数据催化剂 （1）核心问题：这将对获批概率产生多大影响？ （2）重点关注注册性研究和II期后期临床试验 （3）巨大的峰值销售额往往有助于并购溢价，可能带来持续的股价上涨 三 聚焦清晰的发展路径 （1）小分子及其他成熟疗法模式 （2）明确的监管临床终点 （3）清晰的下一步（新药申请/NDA/生物制品许可申请/BLA） 四 生物学复杂且难以预测 （1）并非所有符合这些标准的情况都能成功 （2）尽管分析全面且数据充分，仍无法在许多情况下建立高度信心。 （3）优势来自于市场所忽视的、有依据且差异化的投资逻辑","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767842318853,"gmtModify":1769055253532,"symbols":["SLDB","SGMO","SANA","NTLA","RCKT"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":11861,"likeCount":10,"liked":false,"collected":false,"commentCount":2,"hotComments":[{"id":"519657932968344","author":{"authorId":"3479274787036362","idStr":"3479274787036362","name":"huuou","avatar":"https://static.laohu8.com/picture129","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":11,"starInvestorFlag":false},"content":"指南太牛了，生物科技股有戏！","plainContent":"指南太牛了，生物科技股有戏！","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/519647362978304","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":1470,"displayRows":4,"foldSize":0,"authorId":"3484536045691836"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.518229581341176","cardData":[{"tweetId":"518229581341176","author":{"authorId":"3484536045691836","idStr":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/3f226f5fd9da51c5782d3e591f0bfe54","userType":2,"introduction":"倾向于进入好的业务，并安静地留在那里。","crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"fanSize":4147,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"火箭制药（RCKT) : 发射倒计时，双引擎基因疗法将迎来关键一跃","digest":"除了通过黑夜的道路，人们不能到达黎明。——纪伯伦 这是本老哥新年第一股深度分析，欢迎读者们进来交流讨论。 一 公司简介 火箭制药是一家专注于开发罕见病基因疗法的临床阶段生物技术公司。公司建立了双重的技术平台：一是基于慢病毒的体外基因疗法平台，主要用于治疗血液系统罕见病；二是基于腺相关病毒的体内基因疗法平台，主要用于治疗心脏及神经肌肉疾病。 二 核心管线进展 1. 达农病基因疗法 (RP-A501) 达农病是一种由 LAMP2基因突变引起的X连锁显性遗传病。该突变导致细胞自噬过程受损，糖原和自噬体在心脏、肌肉等组织中异常堆积，从而引发严重且进展迅速的心肌病、骨骼肌无力及智力障碍。男性患者病情尤为凶险，常于青春期或成年早期因心力衰竭死亡，目前除心脏移植外无有效疗法。据公司估计，欧美市场的患者规模约为 15000至30000人。 该管线的关键进展在于其AAV9载体基因疗法RP-A501。该疗法在2025年经历了一次临床暂停挫折，因一位受试者患毛细血管渗漏综合征死亡，但不到3个月之内，公司与FDA达成一致，临床搁置被解除。 公司以调整后的方案（采用3.8 × 10¹³ GC/kg的剂量）重新开始患者给药。此前，基于积极的I期临床数据，该疗法已获得FDA授予的再生医学先进疗法资格，数据显示其能有效修复LAMP2蛋白表达，并在心脏结构和功能等多个终点上表现出持久的改善或稳定。FDA也已认可其采用自然史对照的单臂II期关键试验设计，为其潜在的加速批准路径奠定了基础。 2. 白细胞粘附缺陷症I型基因疗法 (KRESLADI) 白细胞粘附缺陷症I型是一种由 ITGB2基因突变 导致CD18整合素缺陷的罕见常染色体隐性遗传病。该缺陷使得患者白细胞无法迁移至感染部位，导致出生后即出现危及生命的反复严重感染、伤口难以愈合及脐带脱落延迟。重度患者若不接受成功的造血干细胞移植，死亡率极高。该疾病极为罕","plainDigest":"除了通过黑夜的道路，人们不能到达黎明。——纪伯伦 这是本老哥新年第一股深度分析，欢迎读者们进来交流讨论。 一 公司简介 火箭制药是一家专注于开发罕见病基因疗法的临床阶段生物技术公司。公司建立了双重的技术平台：一是基于慢病毒的体外基因疗法平台，主要用于治疗血液系统罕见病；二是基于腺相关病毒的体内基因疗法平台，主要用于治疗心脏及神经肌肉疾病。 二 核心管线进展 1. 达农病基因疗法 (RP-A501) 达农病是一种由 LAMP2基因突变引起的X连锁显性遗传病。该突变导致细胞自噬过程受损，糖原和自噬体在心脏、肌肉等组织中异常堆积，从而引发严重且进展迅速的心肌病、骨骼肌无力及智力障碍。男性患者病情尤为凶险，常于青春期或成年早期因心力衰竭死亡，目前除心脏移植外无有效疗法。据公司估计，欧美市场的患者规模约为 15000至30000人。 该管线的关键进展在于其AAV9载体基因疗法RP-A501。该疗法在2025年经历了一次临床暂停挫折，因一位受试者患毛细血管渗漏综合征死亡，但不到3个月之内，公司与FDA达成一致，临床搁置被解除。 公司以调整后的方案（采用3.8 × 10¹³ GC/kg的剂量）重新开始患者给药。此前，基于积极的I期临床数据，该疗法已获得FDA授予的再生医学先进疗法资格，数据显示其能有效修复LAMP2蛋白表达，并在心脏结构和功能等多个终点上表现出持久的改善或稳定。FDA也已认可其采用自然史对照的单臂II期关键试验设计，为其潜在的加速批准路径奠定了基础。 2. 白细胞粘附缺陷症I型基因疗法 (KRESLADI) 白细胞粘附缺陷症I型是一种由 ITGB2基因突变 导致CD18整合素缺陷的罕见常染色体隐性遗传病。该缺陷使得患者白细胞无法迁移至感染部位，导致出生后即出现危及生命的反复严重感染、伤口难以愈合及脐带脱落延迟。重度患者若不接受成功的造血干细胞移植，死亡率极高。该疾病极为罕","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767495928048,"gmtModify":1768409167627,"symbols":["SLDB","SGMO?_gl=1*wyzcyv*_gcl_au*MTMzNjc0NTkwNi4xNzY3MzE5NDA0","SANA","NTLA","RCKT"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":14232,"likeCount":8,"liked":false,"collected":false,"commentCount":6,"hotComments":[{"id":"518585568634056","author":{"authorId":"3465877826119039","idStr":"3465877826119039","name":"一雨成烟","avatar":"https://static.tigerbbs.com/467d481c895f6bfd337b50860c3b84e2","userType":1,"introduction":"","crmLevel":8,"crmLevelSwitch":0,"fanSize":19,"starInvestorFlag":false},"content":"老哥我全仓all in。还是拿20%买","plainContent":"老哥我全仓all in。还是拿20%买","likeCount":0,"commentType":"hot","coins":0},{"id":"518237012492952","author":{"authorId":"9000000000000165","idStr":"9000000000000165","name":"BruceBryant","avatar":"https://static.tigerbbs.com/0d8b73b1358a3a93eb57cfda4331fb2d","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":32,"starInvestorFlag":false},"content":"火箭双引擎启动，催化剂在望！","plainContent":"火箭双引擎启动，催化剂在望！","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/518229581341176","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2925,"displayRows":4,"foldSize":0,"authorId":"3484536045691836"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.440211569255216","cardData":[{"tweetId":"440211569255216","author":{"authorId":"9000000000000038","idStr":"9000000000000038","name":"中文投资网","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":8,"introduction":"-","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":835,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【盘前必读】特朗普推迟对欧关税美股期指全面走高，新药试验患者突发去世RCKT重挫六成","digest":"本交易日盘前，美股股指期货全面走高，道指涨逾500点，纳斯达克期指涨逾300点，特朗普宣布推迟对欧关税的消息提振了市场，盘前欧洲主要股市也纷纷走高。美国总统唐纳德·特朗普与欧盟委员会主席乌尔苏拉·冯德莱恩通话后，同意将原定于6月1日对欧盟进口商品征收50%关税的计划推迟至7月9日，以便为贸易谈判争取更多时间。个股方面，Rocket Pharmaceuticals宣布，FDA在一名因使用该药物而出现并发症的患者去世后停止了其对Danon病的研究性疗法的试验，盘前股价暴跌六成。中国电商巨头拼多多每股收益和营业收入均大幅不及市场预期，盘前大幅下跌。Skyline Champion每股收益和营业收入均不及市场预期，盘前股价大幅下跌。投资者关注日内经济数据和公司财报。欧洲方面，特朗普推迟关税期限提振投资者情绪，欧洲主要股市小幅走高。石油小幅下跌，黄金大幅走低。美股期指：道琼斯工业股票平均价格指数期货+571.93点，报42239点；纳斯达克100指数期货+327.84点，报21296.5点，标准普尔500股指期货+84.68点，报5900.5点。海外市场：英国富时100指数+0.76%，德国DAX 30指数+0.72%，法国CAC 40指数+0.16%，中国上证指数-0.18%，香港恒生指数+0.43%，日经225指数+0.51%。数据方面投资者可以关注：8:30 4月耐用品订单月率9:00 3月FHFA房价指数月率9:00 3月S&P/CS20座大城市未季调房价指数年率10:00 5月咨商会消费者信心指数10:30 5月达拉斯联储商业活动指数AutoZone(AZO)第三季度每股收益为35.36美元，比市场预期值37.11美元低1.75美元；营收同比增长5.4至44.6亿美元，市场预期值44.2亿美元。Skyline Champion (SKY)第四季度每股收益为0.65美","plainDigest":"本交易日盘前，美股股指期货全面走高，道指涨逾500点，纳斯达克期指涨逾300点，特朗普宣布推迟对欧关税的消息提振了市场，盘前欧洲主要股市也纷纷走高。美国总统唐纳德·特朗普与欧盟委员会主席乌尔苏拉·冯德莱恩通话后，同意将原定于6月1日对欧盟进口商品征收50%关税的计划推迟至7月9日，以便为贸易谈判争取更多时间。个股方面，Rocket Pharmaceuticals宣布，FDA在一名因使用该药物而出现并发症的患者去世后停止了其对Danon病的研究性疗法的试验，盘前股价暴跌六成。中国电商巨头拼多多每股收益和营业收入均大幅不及市场预期，盘前大幅下跌。Skyline Champion每股收益和营业收入均不及市场预期，盘前股价大幅下跌。投资者关注日内经济数据和公司财报。欧洲方面，特朗普推迟关税期限提振投资者情绪，欧洲主要股市小幅走高。石油小幅下跌，黄金大幅走低。美股期指：道琼斯工业股票平均价格指数期货+571.93点，报42239点；纳斯达克100指数期货+327.84点，报21296.5点，标准普尔500股指期货+84.68点，报5900.5点。海外市场：英国富时100指数+0.76%，德国DAX 30指数+0.72%，法国CAC 40指数+0.16%，中国上证指数-0.18%，香港恒生指数+0.43%，日经225指数+0.51%。数据方面投资者可以关注：8:30 4月耐用品订单月率9:00 3月FHFA房价指数月率9:00 3月S&P/CS20座大城市未季调房价指数年率10:00 5月咨商会消费者信心指数10:30 5月达拉斯联储商业活动指数AutoZone(AZO)第三季度每股收益为35.36美元，比市场预期值37.11美元低1.75美元；营收同比增长5.4至44.6亿美元，市场预期值44.2亿美元。Skyline Champion (SKY)第四季度每股收益为0.65美","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1748349540000,"gmtModify":1748500492610,"symbols":["RCKT"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":9,"images":[{"url":"https://static.tigerbbs.com/9cde09c81e224ee083e2e277fd2ab0cb"},{"url":"https://static.tigerbbs.com/17156c37b82446868cdffb4270aafd75"},{"url":"https://static.tigerbbs.com/e16d453060034acba48fe0e58d97fff4"}],"repostCount":0,"viewCount":2098,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/440211569255216","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3703,"displayRows":4,"foldSize":0,"authorId":"9000000000000038"}],"position":0}],"size":4},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20820982","market":"us","labels":[],"media":"sec.gov","original_id":"AN114036126008853-RCKT","pdf_url":"","pub_time":1773177862000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"RCKT","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-008853-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 1.02: Termination of a Material Definitive Agreement;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 5.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/ef20067503_ex5-1.htm","primary":true,"translateUrl":"","linkName":"ef20067503_ex5-1.htm","type":"EX-5.1","id":"NTFILE7kT3QcpEGu62HARt","market":"us","size":19985},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/ef20067503_8k.htm","primary":false,"translateUrl":"","linkName":"ef20067503_8k.htm","type":"8-K","id":"NTFILE4UULUig4uGhQ8cjx","market":"us","size":32303},{"description":"EXHIBIT 10.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/ef20067503_ex10-1.htm","primary":false,"translateUrl":"","linkName":"ef20067503_ex10-1.htm","type":"EX-10.1","id":"NTFILEAT4QVCESFnMsVvJ9","market":"us","size":366938},{"description":"","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/image00001.jpg","primary":false,"translateUrl":"","linkName":"image00001.jpg","type":"GRAPHIC","id":"NTFILE9TrxyFNESYaTNvBc","market":"us","size":2269}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-03-11 05:24","pubTimestamp":1773177862,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 1.02: Termination of a Material Definitive Agreement;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项：签订重大最终协议；第1.02项：重大最终协议的终止；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20778637","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526076551-RCKT","pdf_url":"","pub_time":1772082000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","symbol":"RCKT","title":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","titleType":"年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/0001193125-26-076551-index.htm","us_notice_code":"Form 10-K","us_title_en":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm","primary":true,"translateUrl":"","linkName":"rckt-20251231.htm","type":"10-K","id":"NTFILEB6VZDEHsRquRKNUy","market":"us","size":3042157},{"description":"EX-21.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-ex21_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex21_1.htm","type":"EX-21.1","id":"NTFILE3rJBvLHGVs42tnvS","market":"us","size":1940},{"description":"EX-23.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-ex23_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex23_1.htm","type":"EX-23.1","id":"NTFILE4RcEQzJtwiR2GSSq","market":"us","size":6087},{"description":"EX-31.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-ex31_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex31_1.htm","type":"EX-31.1","id":"NTFILECWDafpZ6gPgyxJGF","market":"us","size":18171},{"description":"EX-31.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-ex31_2.htm","primary":false,"translateUrl":"","linkName":"rckt-ex31_2.htm","type":"EX-31.2","id":"NTFILEHammewgvWPcpcPT1","market":"us","size":18418},{"description":"EX-32.1","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-ex32_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex32_1.htm","type":"EX-32.1","id":"NTFILE2zXYceV269Zao4bf","market":"us","size":15452},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/img4376134_0.gif","primary":false,"translateUrl":"","linkName":"img4376134_0.gif","type":"GRAPHIC","id":"NTFILEGUsGg2fu6jzYjCVf","market":"us","size":191597},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/img4376134_1.jpg","primary":false,"translateUrl":"","linkName":"img4376134_1.jpg","type":"GRAPHIC","id":"NTFILEAnbyNETeFHvzxRgb","market":"us","size":570021},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/img4376134_2.jpg","primary":false,"translateUrl":"","linkName":"img4376134_2.jpg","type":"GRAPHIC","id":"NTFILEFaQE66QUPV6uuv8H","market":"us","size":531326},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/img4376134_3.jpg","primary":false,"translateUrl":"","linkName":"img4376134_3.jpg","type":"GRAPHIC","id":"NTFILELFwzYvefqh1CnS9A","market":"us","size":342749},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/img99582378_0.jpg","primary":false,"translateUrl":"","linkName":"img99582378_0.jpg","type":"GRAPHIC","id":"NTFILE4KBdsxigmiojdgBV","market":"us","size":91152}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"年度报告","pubTime":"2026-02-26 13:00","pubTimestamp":1772082000,"title_zh":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20778628","market":"us","labels":[],"media":"sec.gov","original_id":"AN114036126006981-RCKT","pdf_url":"","pub_time":1772082000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"RCKT","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/0001140361-26-006981-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm","primary":true,"translateUrl":"","linkName":"ef20066645_ex99-1.htm","type":"EX-99.1","id":"NTFILEFgV84ccXmmQUx5Si","market":"us","size":105935},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_8k.htm","primary":false,"translateUrl":"","linkName":"ef20066645_8k.htm","type":"8-K","id":"NTFILECY6JxHwpzrKsMMGc","market":"us","size":29427},{"description":"","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/image00001.jpg","primary":false,"translateUrl":"","linkName":"image00001.jpg","type":"GRAPHIC","id":"NTFILE4jPdWNsxch97nWVQ","market":"us","size":4415}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-26 13:00","pubTimestamp":1772082000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20747066","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001181-RCKT","pdf_url":"","pub_time":1771390800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001181/0001959173-26-001181-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001181/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILECEgvSH3vZS725fRE","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-18 13:00","pubTimestamp":1771390800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20747019","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001176-RCKT","pdf_url":"","pub_time":1771390800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001176/0001959173-26-001176-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001176/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEGe1zBwAj3Zw3Sc1o","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-18 13:00","pubTimestamp":1771390800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20747008","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001175-RCKT","pdf_url":"","pub_time":1771390800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001175/0001959173-26-001175-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001175/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEHWqkXr7EqpiCQgzi","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-18 13:00","pubTimestamp":1771390800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20737036","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001000-RCKT","pdf_url":"","pub_time":1770958800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001000/0001959173-26-001000-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326001000/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE8CgLcXm1NeS3opSB","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-13 13:00","pubTimestamp":1770958800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20736577","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326000994-RCKT","pdf_url":"","pub_time":1770958800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000994/0001959173-26-000994-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000994/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE4GC6MYx2bXmRH3vn","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-13 13:00","pubTimestamp":1770958800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20736563","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326000992-RCKT","pdf_url":"","pub_time":1770958800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000992/0001959173-26-000992-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000992/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE5JNCPk6D4TP444sp","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-13 13:00","pubTimestamp":1770958800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20736477","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326000986-RCKT","pdf_url":"","pub_time":1770958800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000986/0001959173-26-000986-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917326000986/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEGG5oDRQX4kxUaa6r","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-13 13:00","pubTimestamp":1770958800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20425361","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917325007115-RCKT","pdf_url":"","pub_time":1763442000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007115/0001959173-25-007115-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007115/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEDzpPTER2b5RiqPcb","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-18 13:00","pubTimestamp":1763442000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20425272","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917325007109-RCKT","pdf_url":"","pub_time":1763442000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007109/0001959173-25-007109-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007109/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILECAZGMSPBjJX7fGXW","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-18 13:00","pubTimestamp":1763442000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20425255","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917325007106-RCKT","pdf_url":"","pub_time":1763442000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007106/0001959173-25-007106-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007106/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEF5cR489HYuSUqzHn","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-18 13:00","pubTimestamp":1763442000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20425249","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917325007107-RCKT","pdf_url":"","pub_time":1763442000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"RCKT","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007107/0001959173-25-007107-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000195917325007107/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEBGP4KwZuK8LLDnsX","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-18 13:00","pubTimestamp":1763442000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20378497","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525269474-RCKT","pdf_url":"","pub_time":1762405200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"RCKT","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/0001193125-25-269474-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-20250930.htm","primary":true,"translateUrl":"","linkName":"rckt-20250930.htm","type":"10-Q","id":"NTFILEDdnn1uyxviZTEgad","market":"us","size":2315695},{"description":"EX-10.3","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex10_3.htm","primary":false,"translateUrl":"","linkName":"rckt-ex10_3.htm","type":"EX-10.3","id":"NTFILE59EX7WJKBBHJoQaH","market":"us","size":138669},{"description":"EX-10.4","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex10_4.htm","primary":false,"translateUrl":"","linkName":"rckt-ex10_4.htm","type":"EX-10.4","id":"NTFILEHNuZeP4PXY6dZVm8","market":"us","size":19002},{"description":"EX-10.5","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex10_5.htm","primary":false,"translateUrl":"","linkName":"rckt-ex10_5.htm","type":"EX-10.5","id":"NTFILECbrD3kgq1QkbussD","market":"us","size":11092},{"description":"EX-31.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex31_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex31_1.htm","type":"EX-31.1","id":"NTFILEDVJN3m9HM3iHr7PD","market":"us","size":18478},{"description":"EX-31.2","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex31_2.htm","primary":false,"translateUrl":"","linkName":"rckt-ex31_2.htm","type":"EX-31.2","id":"NTFILE6LAzX3HUhzm9A8Ew","market":"us","size":18649},{"description":"EX-32.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/rckt-ex32_1.htm","primary":false,"translateUrl":"","linkName":"rckt-ex32_1.htm","type":"EX-32.1","id":"NTFILECa9DKtRCzLh37Vc6","market":"us","size":15107},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/img174788538_0.jpg","primary":false,"translateUrl":"","linkName":"img174788538_0.jpg","type":"GRAPHIC","id":"NTFILE5HJ9tS7SgTr2MaRj","market":"us","size":1005501},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/img174788538_1.jpg","primary":false,"translateUrl":"","linkName":"img174788538_1.jpg","type":"GRAPHIC","id":"NTFILE2yJxkbJMrQWJFTNo","market":"us","size":1469571},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/img174788538_2.jpg","primary":false,"translateUrl":"","linkName":"img174788538_2.jpg","type":"GRAPHIC","id":"NTFILE3wjr7bLq5d7Nh82i","market":"us","size":1198924},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1281895/000119312525269474/img174788538_3.jpg","primary":false,"translateUrl":"","linkName":"img174788538_3.jpg","type":"GRAPHIC","id":"NTFILE38Ceqg6FVx3EWbLP","market":"us","size":787996}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-11-06 13:00","pubTimestamp":1762405200,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.rocketpharma.com","stockEarnings":[{"period":"1week","weight":0.0603},{"period":"1month","weight":0.5185},{"period":"3month","weight":0.4513},{"period":"6month","weight":0.557},{"period":"1year","weight":-0.4409},{"period":"ytd","weight":0.4017}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rocket Pharmaceuticals, Inc.于1999年7月7日根据特拉华州法律注册成立。该公司是一家完全整合的、处于后期阶段的生物技术公司，专注于开发首创、唯一和同类最佳的基因疗法，具有直接的靶向作用机制和明确的临床终点，用于罕见和破坏性疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.061021},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020726},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062443},{"month":4,"riseRate":0.636364,"avgChangeRate":0.013738},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.036361},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.005129},{"month":7,"riseRate":0.636364,"avgChangeRate":0.138772},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.027706},{"month":9,"riseRate":0.545455,"avgChangeRate":0.094103},{"month":10,"riseRate":0.545455,"avgChangeRate":0.048247},{"month":11,"riseRate":0.545455,"avgChangeRate":0.014665},{"month":12,"riseRate":0.545455,"avgChangeRate":0.102516}],"exchange":"NASDAQ","name":"Rocket Pharmaceuticals, Inc.","nameEN":"Rocket Pharmaceuticals, Inc."},"aProfile":null}}}